IMF Videos Search Content For Healthcare Professional (166) Healthcare Provider (165) Care Partner (128) Patient (128) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (261) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Talquetamab + Teclistamab Show Promising Efficacy in Relapsed/Refractory Multiple Myeloma with EMD January 23, 2026 ASH Kilimanjaro Study: Etentamig Plus Pomalidomide-Dexamethasone Shows Robust Efficacy in Relapsed Myeloma January 21, 2026 ASH CARTITUDE-4: Exceptional Long-Term Outcomes with Cilta-cel in Standard-Risk Relapsed Myeloma January 20, 2026 ASH Anitocabtagene Autoleucel iMMagine-1 Trial: Exceptional Safety and Durability in Relapsed Myeloma January 16, 2026 ASH MajesTEC-3: Teclistamab-Daratumumab Establishes New Standard of Care in Early Relapsed Myeloma January 12, 2026 ASH KLN-1010 In Vivo CAR-T Therapy: Revolutionary Off-the-Shelf Treatment for Multiple Myeloma January 9, 2026 ASH Top Myeloma Research Presented at ASH 2025: Easy-to-Understand Insights for Patients and Care Partners January 7, 2026 ASH Cilta-cel Safety Enhancement: Modifiable Risk Factors for Delayed Neurotoxicity and Non-Relapse Mortality December 19, 2025 ASH IFM2021-01 TecLille Trial: Teclistamab-Daratumumab Combination in Elderly NDMM Patients December 17, 2025 ASH Anitocabtagene Autoleucel for R/R Multiple Myeloma: Preliminary IMMagine-1 Phase 2 Results February 25, 2025 ASH MagnetisMM-3: Long-Term Efficacy & Safety of Less Frequent Elranatamab Dosing in Relapsed Refractory Multiple Myeloma February 25, 2025 ASH Daratumumab vs Active Monitoring in High-Risk Smoldering Multiple Myeloma: Aquila Study Results February 24, 2025 ASH Load More
